
mariantonietta Pisaturo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/416332/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Epidemiology of acute and chronic hepatitis B and delta over the last 5 decades in Italy. World Journal of Gastroenterology, 2014, 20, 7635.	1.4	96
2	HBV superinfection in HCV chronic carriers: A disease that is frequently severe but associated with the eradication of HCV. Hepatology, 2009, 49, 1090-1097.	3.6	94
3	Liver microRNA hsa-miR-125a-5p in HBV Chronic Infection: Correlation with HBV Replication and Disease Progression. PLoS ONE, 2013, 8, e65336.	1.1	72
4	Increased hepatitis C viral load and reactivation of liver disease in HCV RNA-positive patients with onco-haematological disease undergoing chemotherapy. Digestive and Liver Disease, 2012, 44, 49-54.	0.4	71
5	Hepatitis B virus, hepatitis C virus and human immunodeficiency virus infection in undocumented migrants and refugees in southern Italy, January 2012 to June 2013. Eurosurveillance, 2015, 20, 30009.	3.9	70
6	Reactivation of overt and occult hepatitis B infection in various immunosuppressive settings. Journal of Medical Virology, 2011, 83, 1909-1916.	2.5	64
7	Hepatitis B virus infection in undocumented immigrants and refugees in Southern Italy: demographic, virological, and clinical features. Infectious Diseases of Poverty, 2017, 6, 33.	1.5	53
8	Clinical impact of occult hepatitis B virus infection in immunosuppressed patients. World Journal of Hepatology, 2014, 6, 384.	0.8	51
9	<scp>TM</scp> 6 <scp>SF</scp> 2 E167K variant is associated with severe steatosis in chronic hepatitis C, regardless of <scp>PNPLA</scp> 3 polymorphism. Liver International, 2015, 35, 1959-1963.	1.9	51
10	Clinical Presentation, Outcome, and Response to Therapy Among Patients With Acute Exacerbation of Chronic Hepatitis C. Clinical Gastroenterology and Hepatology, 2013, 11, 1174-1180.e11.	2.4	47
11	Efficacy of pegylated interferon α-2a and α-2b in patients with genotype 1 chronic hepatitis C: a meta-analysis. BMC Infectious Diseases, 2012, 12, 357.	1.3	45
12	Association Between a Polymorphism in Cannabinoid Receptor 2 and Severe Necroinflammation in Patients With Chronic Hepatitis C. Clinical Gastroenterology and Hepatology, 2014, 12, 334-340.	2.4	44
13	Hepatitis B virus infection in immigrant populations. World Journal of Hepatology, 2015, 7, 2955.	0.8	43
14	Improvement in the aetiological diagnosis of acute hepatitis C: A diagnostic protocol based on the anti-HCV-IgM titre and IgC Avidity Index. Journal of Clinical Virology, 2009, 46, 222-229.	1.6	42
15	Rituximab-Based Treatment, HCV Replication, and Hepatic Flares. Clinical and Developmental Immunology, 2012, 2012, 1-5.	3.3	42
16	Functional interplay between hepatitis B virus X protein and human miR-125a in HBV infection. Biochemical and Biophysical Research Communications, 2014, 449, 141-145.	1.0	42
17	Epidemiology and management of hepatitis C virus infections in immigrant populations. Infectious Diseases of Poverty, 2019, 8, 17.	1.5	42
18	Role of occult hepatitis B virus infection in chronic hepatitis C. World Journal of Gastroenterology, 2015, 21, 11931.	1.4	40

#	Article	IF	CITATIONS
19	Absence of occult hepatitis C virus infection in patients under immunosupressive therapy for oncohematological diseases. Hepatology, 2011, 54, 1487-1489.	3.6	34
20	Peg-Interferon Plus Ribavirin with or without Boceprevir or Telaprevir for HCV Genotype 1: A Meta-Analysis on the Role of Response Predictors. PLoS ONE, 2014, 9, e94542.	1.1	33
21	Acute Hepatitis with Severe Cholestasis and Prolonged Clinical Course Due to Hepatitis A Virus Ia and Ib Coinfection. Clinical Infectious Diseases, 2007, 44, e73-e77.	2.9	31
22	Clinical and Virological Improvement of Hepatitis B VirusRelated or Hepatitis C VirusRelated Chronic Hepatitis with Concomitant Hepatitis A Virus Infection. Clinical Infectious Diseases, 2006, 42, 1536-1543.	2.9	30
23	HBV transmission from an occult carrier with five mutations in the major hydrophilic region of HBsAg to an immunosuppressed plasma recipient. Journal of Clinical Virology, 2013, 58, 315-317.	1.6	30
24	Reactivation of hepatitis B virus infection in patients with hemo-lymphoproliferative diseases, and its prevention. World Journal of Gastroenterology, 2019, 25, 3299-3312.	1.4	27
25	Lamivudine-resistant HBV strain rtM204V/I in acute hepatitis B. Journal of Infection, 2013, 67, 322-328.	1.7	26
26	Advances in the treatment of hepatitis B virus/hepatitis C virus coinfection. Expert Opinion on Pharmacotherapy, 2014, 15, 1337-1349.	0.9	23
27	Characteristics of liver cirrhosis in Italy: Evidence for a decreasing role of HCV aetiology. European Journal of Internal Medicine, 2017, 38, 68-72.	1.0	23
28	Hepatitis C virus markers in infection by hepatitis C virus: In the era of directly acting antivirals. World Journal of Gastroenterology, 2015, 21, 10749.	1.4	23
29	Treatment of chronic hepatitis C in patients with HIV/HCV coinfection. World Journal of Virology, 2015, 4, 1.	1.3	22
30	Absence of occult HCV infection in patients experiencing an immunodepression condition. Infezioni in Medicina, 2013, 21, 296-301.	0.7	22
31	Hepatitis B Virus (HBV) Reactivation Following Pharmacological Eradication of Hepatitis C Virus (HCV). Viruses, 2019, 11, 850.	1.5	21
32	Interferon-free regimens improve kidney function in patients with chronic hepatitis C infection. Journal of Nephrology, 2019, 32, 763-773.	0.9	21
33	Dementia as Risk Factor for Severe Coronavirus Disease 2019: A Case-Control Study. Frontiers in Aging Neuroscience, 2021, 13, 698184.	1.7	21
34	Molecular epidemiology of hepatitis B virus genotypes circulating in acute hepatitis B patients in the Campania region. Journal of Medical Virology, 2014, 86, 1683-1693.	2.5	20
35	Clinical Findings of HCV Chronic Infection in Undocumented Immigrants and Low-Income Refugees in Three Areas of Southern Italy. Annals of Hepatology, 2018, 17, 47-53.	0.6	20
36	Resistance detection and re-treatment options in hepatitis C virus-related chronic liver diseases after DAA-treatment failure. Infection, 2018, 46, 761-783.	2.3	20

#	Article	IF	CITATIONS
37	HBV/HDV Co-Infection: Epidemiological and Clinical Changes, Recent Knowledge and Future Challenges. Life, 2021, 11, 169.	1.1	19
38	Role of genetic polymorphisms in hepatitis C virus chronic infection. World Journal of Clinical Cases, 2015, 3, 807.	0.3	18
39	The impact of viral molecular diversity on the clinical presentation and outcome of acute hepatitis B in Italy. New Microbiologica, 2015, 38, 137-47.	0.1	16
40	Hepatic flares in chronic hepatitis C: Spontaneous exacerbation vs hepatotropic viruses superinfection. World Journal of Gastroenterology, 2014, 20, 6707.	1.4	15
41	Sustained virological response to antiviral treatment in chronic hepatitis C patients may be predictable by HCV-RNA clearance in peripheral blood mononuclear cells. Journal of Clinical Virology, 2013, 58, 748-750.	1.6	14
42	An estimation of the prevalence of occult HBV infection in Western Europe and in Northern America: A metaâ€analysis. Journal of Viral Hepatitis, 2020, 27, 415-427.	1.0	14
43	Liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfection: Diagnostic methods and clinical impact. World Journal of Hepatology, 2015, 7, 2510.	0.8	14
44	Risk of failure in dual therapy versus triple therapy in naÃ ⁻ ve HIV patients: a systematic review and meta-analysis. Clinical Microbiology and Infection, 2021, 27, 28-35.	2.8	12
45	Hepatitis B virus/hepatitis D virus epidemiology: Changes over time and possible future influence of the SARS-CoV-2 pandemic. World Journal of Gastroenterology, 2021, 27, 7271-7284.	1.4	12
46	Clinical applications of antibody avidity and immunoglobulin M testing in acute HCV infection. Antiviral Therapy, 2012, 17, 1453-1458.	0.6	11
47	HBV molecular epidemiology and clinical condition of immigrants living in Italy. Infection, 2018, 46, 523-531.	2.3	11
48	Management of HBV reactivation in non-oncological patients. Expert Review of Anti-Infective Therapy, 2018, 16, 611-624.	2.0	9
49	HDV infection in immigrant populations. Journal of Medical Virology, 2019, 91, 2049-2058.	2.5	9
50	Blood-borne chronic viral infections in a large cohort of immigrants in southern Italy: A seven-centre, prospective, screening study. Travel Medicine and Infectious Disease, 2020, 35, 101551.	1.5	9
51	Prevalence of occult HBV infection in Western countries. Journal of Medical Virology, 2020, 92, 2917-2929.	2.5	8
52	Hepatitis C virus (HCV) micro-elimination in the hospital setting: The results of the HCV Caserta hospital project. Journal of Infection and Public Health, 2022, 15, 562-565.	1.9	8
53	Low prevalence of HTLV1/2 infection in a population of immigrants living in southern Italy. PLoS Neglected Tropical Diseases, 2018, 12, e0006601.	1.3	7
54	Epidemiology of HCV and HBV in a High Endemic Area of Southern Italy: Opportunities from the COVID-19 Pandemic—Standardized National Screening or One Tailored to Local Epidemiology?. Biology, 2022, 11, 609.	1.3	7

#	Article	IF	CITATIONS
55	Direct acting antivirals treatment for hepatitis C virus infection does not increase the incidence of de novo hepatocellular carcinoma occurrence. Medicine (United States), 2020, 99, e18948.	0.4	6
56	The Reactivation of Occult HBV Infection Emerging with the Case of Acute Hepatitis B in the Wife of a Subject Treated with Rituximab-Based Chemotherapy. Antiviral Therapy, 2015, 20, 349-352.	0.6	5
57	Patients with HCV genotype-1 who have failed a direct-acting antiviral regimen: virological characteristics and efficacy of retreatment. Antiviral Therapy, 2019, 24, 485-493.	0.6	5
58	Hepatitis B Virus Genotypes, Epidemiological Characteristics, and Clinical Presentation of HBV Chronic Infection in Immigrant Populations Living in Southern Italy. Hepatitis Monthly, 2017, 17, .	0.1	5
59	Risk and Prevention of Hepatitis B Virus Reactivation during Immunosuppression for Non-Oncological Diseases. Journal of Clinical Medicine, 2021, 10, 5201.	1.0	5
60	Hepatitis C late relapse in patients with directly acting antiviralâ€related sustained virological response at week 12. Liver International, 2019, 39, 844-853.	1.9	4
61	Genetic Variability in Patients with HCV-Related Hepatocellular Carcinoma. Infection and Drug Resistance, 2021, Volume 14, 5199-5208.	1.1	4
62	Impact of DAA-Based Regimens on HCV-Related Extra-Hepatic Damage: A Narrative Review. Advances in Experimental Medicine and Biology, 2020, 1323, 115-147.	0.8	3
63	Role of ITPA and IL28B variants in the management of chronic hepatitis C treatment. Infezioni in Medicina, 2015, 23, 134-9.	0.7	3
64	Absence of occult HCV infection in HIV-positive patients. Journal of Infection, 2012, 64, 436-437.	1.7	2
65	No effect of MTP polymorphisms on PNPLA3 in HCV-correlated steatosis. Infezioni in Medicina, 2018, 26, 244-248.	0.7	2
66	HBeAg Levels Vary across the Different Stages of HBV Infection According to the Extent of Immunological Pressure and Are Associated with Therapeutic Outcome in the Setting of Immunosuppression-Driven HBV Reactivation. Biomedicines, 2021, 9, 1352.	1.4	1
67	Hepatitis B Virus Genotypes, Epidemiological Characteristics and Clinical Presentation of HBV Chronic Infection in Immigrant Populations Living in Southern Italy. Hepatitis Monthly, 2017, 17, .	0.1	0